| Sku |
AAP35768 |
| Old sku |
AAPP07020 |
| Price |
$99.00 |
| Name |
MAGEA9 Peptide - middle region (AAP35768) |
| Purchase info |
To purchase this peptide:
- Copy peptide sku
- Click on this link
- Paste into field "Peptide Sku"
|
| Size |
100 ug |
| Gene |
MAGEA9 |
| Alias symbols |
MAGE9, MGC8421, CT1.9, MAGEA9B |
| Gene id |
4108 |
| Description of target |
MAGEA9 is a member of the MAGEA gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita. This pseudogene is a member of the cytochrome P450 gene superfamily. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. It is possible that, in rare cases, a combination of two SNPs in this gene may result in an open reading frame encoding a functional enzyme which metabolizes codeine to morphine. This locus is part of a cluster of cytochrome P450 genes on chromosome 22q13.1. This gene is a member of the MAGEA gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita. |
| Swissprot id |
P43362 |
| Protein accession num |
NP_005356 |
| Nucleotide accession num |
NM_005365 |
| Protein size |
315 amino acids |
| Molecular weight |
35kDa |
| Application |
WB |
| Quality control |
The peptide is characterized by mass spectroscopy |
| Key reference |
Oehlrich,N., (2005) Int. J. Cancer 117 (2), 256-264 |
| Description |
This is a synthetic peptide designed for use in combination with anti-MAGEA9 antibody (Catalog #: ARP35768_P050) made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details. |
| Product format |
Lyophilized powder |
| Reconstitution and storage |
Add 100ul of sterile PBS. Final peptide concentration is 1 mg/ml in PBS. For longer periods of storage, store at -20C. Avoid repeat freeze-thaw cycles. |
| Lead time |
Domestic: within 24 hours delivery International: 3-5 business days |
| Protocol |
|
| Tips |
See our General FAQ page. |
| Availability |
In Stock |
